KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Receivables: 2017-2024

Historic Receivables for Moderna (MRNA) over the last 8 years, with Dec 2024 value amounting to $757.0 million.

  • Moderna's Receivables fell 25.81% to $2.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 billion, marking a year-over-year decrease of 36.89%. This contributed to the annual value of $757.0 million for FY2024, which is 53.93% down from last year.
  • According to the latest figures from FY2024, Moderna's Receivables is $757.0 million, which was down 53.93% from $1.6 billion recorded in FY2023.
  • In the past 5 years, Moderna's Receivables ranged from a high of $3.2 billion in FY2021 and a low of $757.0 million during FY2024.
  • Its 3-year average for Receivables is $1.3 billion, with a median of $1.4 billion in 2022.
  • Its Receivables has fluctuated over the past 5 years, first soared by 11,379.84% in 2020, then plummeted by 55.18% in 2022.
  • Over the past 5 years, Moderna's Receivables (Yearly) stood at $1.4 billion in 2020, then skyrocketed by 130.26% to $3.2 billion in 2021, then crashed by 55.18% to $1.4 billion in 2022, then grew by 13.62% to $1.6 billion in 2023, then slumped by 53.93% to $757.0 million in 2024.